SCHEMBL479442

SCHEMBL479442

CCOC(=O)c1ccc2c(c1)NC(=O)C2=C(Nc1ccc(C(C)(C)N)c([N+](=O)[O-])c1)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.42
ALDH1A1 P00352 5/20 0.42
GAA P10253 2/20 0.42
RXFP1 Q9HBX9 1/20 0.42
KMT2A Q03164 4/20 0.40
MAPT P10636 5/20 0.37
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
PKM P14618 1/20 0.37
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
MAPK1 P28482 3/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL480387 0.92 CASP3 (0.39) SMN1; SMN2ALDH1A1KMT2AMAPTNPC1
SCHEMBL2123987 0.89 RXFP1 (0.45) SMN1; SMN2ALDH1A1GAARXFP1KMT2A
SCHEMBL480689 0.88 RXFP1 (0.45) SMN1; SMN2ALDH1A1GAARXFP1KMT2A
SCHEMBL480445 0.88 RXFP1 (0.45) SMN1; SMN2ALDH1A1GAARXFP1KMT2A
SCHEMBL2121050 0.87 RXFP1 (0.44) SMN1; SMN2ALDH1A1GAARXFP1KMT2A
SCHEMBL480447 0.87 RXFP1 (0.44) SMN1; SMN2ALDH1A1GAARXFP1KMT2A
SCHEMBL19133988 0.87 RXFP1 (0.44) SMN1; SMN2ALDH1A1GAARXFP1KMT2A
SCHEMBL479819 0.87 RXFP1 (0.44) SMN1; SMN2ALDH1A1GAARXFP1KMT2A
SCHEMBL2121157 0.86 RXFP1 (0.44) SMN1; SMN2ALDH1A1GAARXFP1KMT2A
SCHEMBL479440 0.85 SMN1; SMN2 (0.42) SMN1; SMN2ALDH1A1GAARXFP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9844572-B2 Promotion of neuronal integration in neural stem cell grafts LIFE & BRAIN GMBH (DE) 2017-12-19 US disclosed
EP-2411034-B1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS LIFE & BRAIN GMBH (DE) 2017-07-26 EP disclosed
US-20120093832-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS LIFE & BRAIN GMBH (DE) 2012-04-19 US disclosed
EP-2411034-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS Life & Brain GmbH (DE) 2012-02-01 EP disclosed
WO-2010108665-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS LIFE & BRAIN GMBH (DE) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120093832-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS DCX, NGF, BDNF SMN1; SMN2 60/4885ALDH1A1 175/4885GAA 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.